Clinical Trial Update: Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension

View source ↗

Summary

An upcoming clinical trial evaluating patient-reported outcomes and adherence after switching from inhaled iloprost to oral selexipag in pulmonary arterial hype…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Uptravi (selexipag) (selexipag)
• Ventavis (iloprost) (iloprost)

Snippet

Sponsor: University of Sao Paulo General Hospital | Conditions: Pulmonary Arterial Hypertension (PAH) | Status: NOT_YET_RECRUITING